Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

94.04USD
22 Jul 2019
Change (% chg)

$0.48 (+0.51%)
Prev Close
$93.56
Open
$94.46
Day's High
$94.58
Day's Low
$93.85
Volume
2,617,936
Avg. Vol
2,463,080
52-wk High
$96.31
52-wk Low
$74.97

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $224,870.50
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.17

Financials

  NVS Industry Sector
P/E (TTM): 31.31 29.88 32.67
EPS (TTM): 2.74 -- --
ROI: 6.14 14.90 14.49
ROE: 9.19 16.02 15.79

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS

Jul 19 2019

Novartis's older MS drug Gilenya wins Chinese approval

ZURICH Novartis's Gilenya multiple sclerosis drug has won approval in China, the Swiss drugmaker said on Friday, as the company expands further into the world's most-populous country's growing healthcare sector.

Jul 19 2019

Novartis's older MS drug Gilenya wins Chinese approval

ZURICH, July 19 Novartis's Gilenya multiple sclerosis drug has won approval in China, the Swiss drugmaker said on Friday, as the company expands further into the world's most-populous country's growing healthcare sector.

Jul 19 2019

UPDATE 2-ECB report eases earnings pain for European stocks

* Italy's banks jump on prospect of snap elections (Updates to close)

Jul 18 2019

BRIEF-Novartis CEO Expects Q4 European Commission Approval For Zolgensma

* NOVARTIS CEO SAYS EXPECTS Q4 EUROPEAN COMMISSION APPROVAL FOR ZOLGENSMA Further company coverage: (Reporting by John Miller)

Jul 18 2019

BRIEF-Novartis CEO Says U.S. Gov't Policy Environment Very Fluid

* NOVARTIS CEO SAYS PLANS TO INITIATE DISCUSSIONS WITH FDA OVER INTRATHECAL ADMINISTRATION OF ZOLGENSMA LATER THIS YEAR

Jul 18 2019

BRIEF-Lifemax Laboratories Says FDA Granted Rare Pediatric Disease Designation To Lm-030

* LIFEMAX LABORATORIES - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION TO LM-030, AN INVESTIGATIONAL THERAPY LICENSED FROM NOVARTIS Source text for Eikon: Further company coverage:

Jul 18 2019

Novartis raises full-year targets, aims to settle U.S. lawsuit

ZURICH Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.

Jul 18 2019

UPDATE 2-Novartis raises full-year targets, aims to settle U.S. lawsuit

* CEO says $700 mln set aside for potential lawsuit settlement

Jul 18 2019

Novartis CEO sets aside $700 million to settle doctor bribery lawsuit

ZURICH Novartis Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close the chapter on allegedly aggressive business practices that exposed it to litigation risks.

Jul 18 2019

Earnings vs. Estimates